MCID: ISC004
MIFTS: 61

Ischemia

Categories: Blood diseases, Cardiovascular diseases, Metabolic diseases

Aliases & Classifications for Ischemia

MalaCards integrated aliases for Ischemia:

Name: Ischemia 12 54 44 15 17 70
Acute Coronary Syndrome 70

Classifications:



External Ids:

Disease Ontology 12 DOID:326
MeSH 44 D007511
NCIt 50 C34738
SNOMED-CT 67 52674009
UMLS 70 C0022116 C0948089

Summaries for Ischemia

Disease Ontology : 12 A vascular disease that is characterized by a restriction in blood supply to tissues.

MalaCards based summary : Ischemia, also known as acute coronary syndrome, is related to limb ischemia and retinal ischemia, and has symptoms including muscle weakness, polydipsia and angina pectoris. An important gene associated with Ischemia is ENSG00000284946 (), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Development Angiotensin activation of ERK. The drugs Diphenhydramine and Zolpidem have been mentioned in the context of this disorder. Affiliated tissues include endothelial, bone marrow and heart, and related phenotypes are cardiovascular system and behavior/neurological

Wikipedia : 73 Ischemia or ischaemia is a restriction in blood supply to tissues, causing a shortage of oxygen that is... more...

Related Diseases for Ischemia

Diseases related to Ischemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1600)
# Related Disease Score Top Affiliating Genes
1 limb ischemia 33.3 VEGFA NOS3 HIF1A CXCL12 ACE
2 retinal ischemia 33.1 VEGFA SOD1 HIF1A CXCL12 CASP3
3 transient cerebral ischemia 33.1 SOD2 CDK5 CASP3
4 vascular disease 32.6 VEGFA SOD1 PON1 NOS3 HMOX1 EPO
5 lipoprotein quantitative trait locus 32.6 VEGFA PON1 NOS3 HIF1A CASP3 ADORA1
6 nonarteritic anterior ischemic optic neuropathy 32.3 VEGFA NOS3 ACE
7 ischemic colitis 32.3 VEGFA HMOX1 HIF1A ACE
8 myocardial stunning 32.2 SOD1 ADORA3 ADORA1 ACE
9 microvascular complications of diabetes 5 32.2 VEGFA SOD2 PON1 NOS3 HIF1A CXCL12
10 myocardial infarction 32.2 VEGFA PON1 NOS3 HMOX1 HIF1A EPO
11 brain edema 32.1 VEGFA SOD1 HMOX1
12 exudative vitreoretinopathy 1 32.1 VEGFA NOS3 HIF1A EPO
13 microvascular complications of diabetes 2 32.1 EPO ACE
14 microvascular complications of diabetes 1 32.1 VEGFA HIF1A EPO CXCL12
15 coronary stenosis 32.0 PON1 CXCL12 ACE
16 peripheral artery disease 31.9 VEGFA NOS3 HMOX1 HIF1A ACE
17 hyperglycemia 31.9 SOD2 SOD1 PRKAA2 NOS3 HIF1A
18 respiratory failure 31.9 VEGFA SOD1 EPO ACE
19 testicular torsion 31.8 NOS3 CASP3 ACE
20 anoxia 31.8 SOD1 ADORA1
21 pulmonary edema 31.7 NOS3 HMOX1 HIF1A EPO ACE
22 end stage renal disease 31.6 VEGFA SOD2 PON1 NOS3 EPO ACE
23 arteriosclerosis 31.6 PON1 NOS3 HMOX1 HIF1A CXCL12 ACE
24 carotid stenosis 31.6 VEGFA NOS3 ACE
25 atherosclerosis susceptibility 31.6 VEGFA PON1 NOS3 ACE
26 pre-eclampsia 31.5 VEGFA SOD1 PON1 NOS3 HMOX1 HIF1A
27 congestive heart failure 31.5 VEGFA NOS3 EPO ADORA1 ACE
28 chronic kidney disease 31.5 VEGFA SOD1 PON1 NOS3 HMOX1 EPO
29 retinal vascular disease 31.4 VEGFA NOS3 HIF1A CASP3 ACE
30 vascular dementia 31.4 VEGFA SOD1 PON1 CASP3 APP ACE
31 stroke, ischemic 31.4 SOD2 PON1 NOS3 CXCL12 CASP3 ADORA3
32 pheochromocytoma 31.3 VEGFA HIF1A EPO EGR1 CASP3 ACE
33 heart disease 31.3 VEGFA SOD2 SOD1 PON1 NOS3 HMOX1
34 retinal artery occlusion 31.3 VEGFA HMOX1 ACE
35 macular retinal edema 31.3 VEGFA CXCL12 ACE
36 diabetes mellitus 31.2 VEGFA SOD2 SOD1 PON1 NOS3 MAPK8IP1
37 retinal vein occlusion 31.2 VEGFA CXCL12 ACE
38 neuroblastoma 31.2 VEGFA SOD1 HMOX1 HIF1A EGR1 CXCL12
39 type 2 diabetes mellitus 31.2 VEGFA SOD2 SOD1 PRKAA2 PON1 NOS3
40 pulmonary hypertension 31.2 VEGFA NOS3 HMOX1 HIF1A ACE
41 sleep apnea 31.2 VEGFA NOS3 HIF1A EPO ACE
42 eclampsia 31.2 VEGFA NOS3 ACE
43 diabetic neuropathy 31.1 VEGFA SOD2 PON1 EPO ACE
44 asphyxia neonatorum 31.1 HIF1A EPO CASP3
45 renovascular hypertension 31.1 SOD1 NOS3 HMOX1 ACE
46 polycythemia 31.0 VEGFA HIF1A EPO ACE
47 deficiency anemia 31.0 SOD1 PON1 HMOX1 HIF1A EPO ACE
48 diabetic macular edema 31.0 VEGFA SOD2 NOS3 HIF1A EPO
49 orthostatic intolerance 31.0 NOS3 EPO ACE
50 hypertension, essential 31.0 VEGFA SOD2 SOD1 PON1 NOS3 HMOX1

Graphical network of the top 20 diseases related to Ischemia:



Diseases related to Ischemia

Symptoms & Phenotypes for Ischemia

UMLS symptoms related to Ischemia:


muscle weakness; polydipsia; angina pectoris; anoxemia

MGI Mouse Phenotypes related to Ischemia:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADORA1 ADORA3 APP CASP3 CXCL12
2 behavior/neurological MP:0005386 10.45 ACE ADORA1 ADORA3 APP CASP3 CDK5
3 homeostasis/metabolism MP:0005376 10.44 ACE ADORA1 ADORA3 APP CASP3 CDK5
4 cellular MP:0005384 10.4 APP CASP3 CXCL12 EGR1 EPO HIF1A
5 hematopoietic system MP:0005397 10.37 ACE ADORA3 APP CASP3 CXCL12 EGR1
6 growth/size/body region MP:0005378 10.35 ACE ADORA1 APP CASP3 EGR1 HIF1A
7 immune system MP:0005387 10.34 ACE ADORA3 APP CASP3 CXCL12 EGR1
8 mortality/aging MP:0010768 10.28 ACE ADORA1 APP CASP3 CDK5 CXCL12
9 endocrine/exocrine gland MP:0005379 10.25 ACE CASP3 EGR1 HIF1A HMOX1 MAPK8IP1
10 integument MP:0010771 10.22 ADORA1 ADORA3 APP CASP3 CDK5 EGR1
11 liver/biliary system MP:0005370 10.17 ACE CXCL12 EGR1 EPO HIF1A HMOX1
12 nervous system MP:0003631 10.17 ACE ADORA1 APP CASP3 CDK5 CXCL12
13 muscle MP:0005369 10.11 APP CASP3 CXCL12 EPO HIF1A HMOX1
14 limbs/digits/tail MP:0005371 10 APP EGR1 EPO HIF1A HMOX1 NOS3
15 renal/urinary system MP:0005367 9.96 ACE ADORA1 ADORA3 CASP3 HIF1A HMOX1
16 reproductive system MP:0005389 9.9 ACE APP CASP3 CXCL12 EGR1 HMOX1
17 respiratory system MP:0005388 9.65 ADORA1 ADORA3 CASP3 CDK5 EGR1 EPO
18 vision/eye MP:0005391 9.28 ACE ADORA3 CASP3 EGR1 HIF1A NOS3

Drugs & Therapeutics for Ischemia

Drugs for Ischemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 841)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
2
Zolpidem Approved Phase 4 82626-48-0 5732
3
Promethazine Approved, Investigational Phase 4 60-87-7 4927
4
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
5
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
7
Capsaicin Approved Phase 4 404-86-4 1548943
8
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
9
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
10
Etomidate Approved Phase 4 33125-97-2 36339 667484
11
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
12
Nadroparin Approved, Investigational Phase 4
13
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
14
Insulin glargine Approved Phase 4 160337-95-1
15
Dobutamine Approved Phase 4 34368-04-2 36811
16
Tocopherol Approved, Investigational Phase 4 1406-66-2
17
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
18
Fondaparinux Approved, Investigational Phase 4 104993-28-4
19
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
20
Famotidine Approved Phase 4 76824-35-6 3325
21
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
22
Enoxaparin Approved Phase 4 9005-49-6 772
23
Acetaminophen Approved Phase 4 103-90-2 1983
24
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
25
Thrombin Approved, Investigational Phase 4
26
Simvastatin Approved Phase 4 79902-63-9 54454
27
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
28
Streptokinase Approved, Investigational Phase 4 9002-01-1
29
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
30
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
31
Pravastatin Approved Phase 4 81093-37-0 54687
32
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
33
Glyburide Approved Phase 4 10238-21-8 3488
34
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
35
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
36
Ramipril Approved Phase 4 87333-19-5 5362129
37
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
38
Abciximab Approved Phase 4 143653-53-6
39
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
40
Atenolol Approved Phase 4 29122-68-7 2249
41
Citalopram Approved Phase 4 59729-33-8 2771
42
Esmolol Approved Phase 4 81147-92-4, 103598-03-4 59768
43
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
44
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
45
Polyestradiol phosphate Approved Phase 4 28014-46-2
46
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
47
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
48
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
49
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
50
Hydroxychloroquine Approved Phase 4 118-42-3 3652

Interventional clinical trials:

(show top 50) (show all 5592)
# Name Status NCT ID Phase Drugs
1 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
2 The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
3 Intensive Lipid Lowering Treatment in Patients With Non-ST-elevation ACS Undergoing Percutaneous Coronary Intervention Unknown status NCT01040936 Phase 4 Atorvastatin;Atorvastatin
4 Acute Rosuvastatin for Preventing Myocardial Damage in Patients With Acute Coronary Syndrome Unknown status NCT01245803 Phase 4 additional rosuvastatin loading;placebo control
5 Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study Unknown status NCT02299245 Phase 4 rosuvastatin
6 A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome Unknown status NCT03007524 Phase 4 High dose Rosuvastatin;Low dose Rosuvastatin
7 Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS) Unknown status NCT02592720 Phase 4 cocktail
8 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
9 Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial. Unknown status NCT01572129 Phase 4 Clopidogrel;Placebo
10 Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4 TELMISARTAN;RAMIPRIL
11 Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit Unknown status NCT01920334 Phase 4 Zolpidem CR 12.5mg;Placebo
12 Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial Unknown status NCT02628587 Phase 4 Generic clopidogrel;Patent clopidogrel
13 A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography Unknown status NCT02464397 Phase 4
14 A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome. Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
15 Intervention Study Measuring Inflammatory Cytokine Levels in the Serum of Patients Who Underwent an Acute MI, and the Influence of Vitamin D on These Levels Unknown status NCT01115842 Phase 4 Vitamin D
16 Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome Unknown status NCT02809820 Phase 4 Carvedilol;Metoprolol
17 Comparative Effectiveness and Safety Analysis of Low-dose and Standard-dose Ticagrelor in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Unknown status NCT03381755 Phase 4 half-dose ticagrelor;standard-dose ticagrelor
18 COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial) Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
19 Nanjing First Hospital, Nanjing Medical University Unknown status NCT01171911 Phase 4 Nicardipine , Esmolol
20 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
21 Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study) Unknown status NCT02792712 Phase 4 Ticagrelor;Clopidogrel
22 Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest. Unknown status NCT02341729 Phase 4 ticagrelor
23 Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly Unknown status NCT02317198 Phase 4 Clopidogrel;Ticagrelor or Prasugrel
24 Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome Unknown status NCT02015988 Phase 4 Fenofibrate;Simvastatin
25 Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study Unknown status NCT03016611 Phase 4 Chewing Ticagrelor LD;Chewing Prasugrel LD
26 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
27 Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel Unknown status NCT02032290 Phase 4 ticagrelor loading;Clopidogrel loading
28 A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes Unknown status NCT02077257 Phase 4 Rosuvastatin
29 Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial. Unknown status NCT01906749 Phase 4 Colchicine;Placebo
30 An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI(EARLY-MYO II) Unknown status NCT02201667 Phase 4 Ticagrelor;clopidogrel;Aspirin
31 evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients Unknown status NCT02932592 Phase 4
32 Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction Unknown status NCT03182855 Phase 4 Ticagrelor;Cangrelor Tetrasodium
33 Customized Choice of P2Y12 Oral Receptor Blocker Based on Phenotype Assessment Via Point of Care Testing Unknown status NCT01477775 Phase 4 Oral P2Y12 receptor blocker;Customized choice for the oral P2Y12 receptor blocker
34 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
35 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
36 A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS Unknown status NCT02284503 Phase 4 Rosuvastatin
37 Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial Unknown status NCT01690832 Phase 4 standard saline infusion;fenoldopam infusion
38 Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist Unknown status NCT02627521 Phase 4 Ticagrelor
39 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
40 Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS) Unknown status NCT02868203 Phase 4
41 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
42 Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome Unknown status NCT01068093 Phase 4 Ezetimibe
43 Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome Unknown status NCT01170338 Phase 4 Varenicline 100 mg by mouth twice daily;control
44 Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome Unknown status NCT02379676 Phase 4 Ticagrelor;Clopidogrel
45 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
46 Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome Unknown status NCT02049229 Phase 4
47 Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03150667 Phase 4 Ticagrelor;Clopidogrel
48 Randomized Controlled Study of a Rapid "Rule Out" Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes Unknown status NCT00933400 Phase 4
49 N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
50 OCT Evaluation of Stent Struts Re-endothelization in Patients With Acute Coronary Syndromes: a Comparison of the Intrepide™ Stent vs. Taxus™ Unknown status NCT00914420 Phase 4

Search NIH Clinical Center for Ischemia

Cochrane evidence based reviews: ischemia

Genetic Tests for Ischemia

Anatomical Context for Ischemia

MalaCards organs/tissues related to Ischemia:

40
Endothelial, Bone Marrow, Heart, Bone, Spinal Cord, Liver, Brain

Publications for Ischemia

Articles related to Ischemia:

(show top 50) (show all 54440)
# Title Authors PMID Year
1
Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia. 61 54
20235222 2010
2
Ischemia induces endoplasmic reticulum stress and cell apoptosis in human brain. 61 54
20347937 2010
3
Early and prominent alterations in hemodynamics, signaling, and gene expression following renal ischemia in sickle cell disease. 54 61
20107113 2010
4
Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia. 54 61
19822191 2010
5
Vascular responses to hypoxia and ischemia. 61 54
19729615 2010
6
The possible mechanism for impaired angiogenesis after transient focal ischemia in type 2 diabetic GK rats: different expressions of angiostatin and vascular endothelial growth factor. 54 61
19932587 2010
7
Protective effect of albumin on VEGF and brain edema in acute ischemia in rats. 54 61
20138968 2010
8
Brief exposure to carbon monoxide preconditions cardiomyogenic cells against apoptosis in ischemia-reperfusion. 54 61
20152804 2010
9
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. 54 61
20298924 2010
10
Effects of AMP-activated protein kinase in cerebral ischemia. 61 54
20010958 2010
11
Heme oxygenase-1 protects donor livers from ischemia/reperfusion injury: the role of Kupffer cells. 54 61
20222175 2010
12
Angiogenic effects of stromal cell-derived factor-1 (SDF-1/CXCL12) variants in vitro and the in vivo expressions of CXCL12 variants and CXCR4 in human critical leg ischemia. 54 61
20206813 2010
13
Selective intrarenal human A1 adenosine receptor overexpression reduces acute liver and kidney injury after hepatic ischemia reperfusion in mice. 54 61
20065944 2010
14
Loss of clusterin expression worsens renal ischemia-reperfusion injury. 54 61
20007348 2010
15
A highlight of myoglobin diversity: the nitrite reductase activity during myocardial ischemia-reperfusion. 61 54
19836457 2010
16
Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia. 54 61
20133634 2010
17
Cardiac protection by basic fibroblast growth factor from ischemia/reperfusion-induced injury in diabetic rats. 61 54
20190407 2010
18
Evidence for caspase effects on release of cytochrome c and AIF in a model of ischemia in cortical neurons. 61 54
19944742 2010
19
Allopurinol, xanthine oxidase, and cardiac ischemia. 61 54
19794315 2009
20
Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion. 54 61
19920350 2009
21
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death. 61 54
19850943 2009
22
Role of peroxynitrite and recombinant human manganese superoxide dismutase in reducing ischemia-reperfusion renal tissue injury. 54 61
19917352 2009
23
Up-regulation of ICAM-1 during cold ischemia triggers early neutrophil infiltration in human pancreas allograft reperfusion. 54 61
19917355 2009
24
Association of cystatin C with ischemia in patients with coronary heart disease. 61 54
19816865 2009
25
Retinal ischemia-induced apoptosis is associated with alteration in Bax and Bcl-x(L) expression rather than modifications in Bak and Bcl-2. 61 54
19862336 2009
26
Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. 61 54
19576596 2009
27
Ischemia activates the ATF6 branch of the endoplasmic reticulum stress response. 54 61
19622751 2009
28
Mesenchymal stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia. 61 54
19344900 2009
29
Lentiviral-mediated overexpression of Bcl-xL protects primary endothelial cells from ischemia/reperfusion injury-induced apoptosis. 61 54
19716047 2009
30
Enterocyte shedding and epithelial lining repair following ischemia of the human small intestine attenuate inflammation. 54 61
19753114 2009
31
Exposure of human keratinocytes to ischemia, hyperglycemia and their combination induces oxidative stress via the enzymes inducible nitric oxide synthase and xanthine oxidase. 54 61
19539448 2009
32
Hypothermia attenuates ischemia/reperfusion-induced endothelial cell apoptosis via alterations in apoptotic pathways and JNK signaling. 54 61
19596001 2009
33
N-terminal pro-B-type natriuretic peptide and inducible ischemia in the Heart and Soul Study. 61 54
19685518 2009
34
Increased expression of monocarboxylate transporter 1 after acute ischemia of isolated, perfused mouse hearts. 54 61
19604494 2009
35
Adrenomedullin ameliorates ischemia reperfusion injury in rat livers. 54 61
19663270 2009
36
The E-selectin ligand basigin/CD147 is responsible for neutrophil recruitment in renal ischemia/reperfusion. 54 61
19443639 2009
37
Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. 54 61
19456402 2009
38
Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial. 61 54
19371824 2009
39
Transient postprandial ischemia is associated with increased intestinal fatty acid binding protein in patients with chronic gastrointestinal ischemia. 61 54
19279473 2009
40
Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. 54 61
19117950 2009
41
[Biochemical markers in the diagnosis of acute coronary syndrome]. 61 54
19681456 2009
42
Ischemia alters the expression of connexins in the aged human brain. 54 61
19794823 2009
43
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. 61 54
18812468 2009
44
Pretreatment with bone morphogenetic protein-7 (BMP-7) mimics ischemia preconditioning following intestinal ischemia/reperfusion injury in the intestine and liver. 61 54
18461025 2008
45
Markers of acute coronary syndrome in emergency room. 54 61
18971915 2008
46
Heart-type Fatty acid-binding protein in Acute Myocardial infarction Evaluation (FAME): background and design of a diagnostic study in primary care. 54 61
18412949 2008
47
Effect of hemodialysis on traditional and innovative cardiac markers. 61 54
18200568 2008
48
Ultrasound enhanced thrombolysis: applications in acute cerebral ischemia. 61 54
19513336 2007
49
Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. 54 61
18373327 2007
50
Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model. 61 54
16547766 2006